Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

274.16 +1.75 (+0.64%)
Streaming Delayed Price Updated: 11:58 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
53 54 Next >
Is Amgen's Dividend Safe?
Despite multiple headwinds, the biotech's dividend appears to be a safe play for income investors. 
Via The Motley Fool
The Blazing Weight-Loss Drug Battle: Can Anyone Unseat Undisputed Leaders Novo Nordisk And Lilly?
An overweight world is hungry for new treatments. For now, two companies own the market. 
Via Investor's Business Daily
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
Analyst Expectations for Amgen's Future
Via Benzinga
Activision Surges 10% As Judge OK's Microsoft Acquisition Deal
Following a federal judge's OK of Microsoft's acquisition, Activision shares soared 10%, marking their strongest performance in over a year. The FTC can appeal. 
Via MarketBeat
What Does Amgen's Debt Look Like?
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $400 Today
Via Benzinga
Amgen: Are Its Golden Days Over?
AMGN has grown revenues by a CAGR of 4.73%, net income by 5.38%, and dividends by an impressive 21.11%. 
Via Talk Markets
European Regulator Expands Ozempic Probe To Include Other Weight Loss Drugs Over Suicide Risks
Via Benzinga
Activision Stock Jumps As U.S. Judge Clears Hurdle To Microsoft Buyout
Activision stock rocketed after a court allowed Microsoft to proceed with its $69 billion acquisition of the video game publisher. 
Via Investor's Business Daily
Viridian Wants To Take On Horizon; Why This Update In Thyroid Eye Disease Fell Flat
Shares tumbled after the biotech company unveiled the results of its chronic TED treatment. 
Via Investor's Business Daily
2 Struggling Dividend Growth Stocks That Could Make You Richer
Let's look beyond these drugmakers' ongoing issues. 
Via The Motley Fool
Treasury Yields Spiking As Market Looks Ahead To Jobs Data, Raising Valuation Concerns
(Thursday market open) Things are heating up, and we’re not just talking about the July weather. A week from the start of Q2 earnings season, Wall Street is on tenterhooks awaiting tomorrow’s crucial... 
Via Benzinga
How Is The Market Feeling About Amgen?
Via Benzinga
7 Analysts Have This to Say About Amgen
Via Benzinga
A Look Into Amgen Inc's Price Over Earnings
Via Benzinga
3 Biotech Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2025
In researching this article, we used AI to help make predictions for potential triple-digit return biotech stocks by 2025 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
15 Stocks Up, 15 Stocks Down: A Look At The Dow Jones Industrial Average Halfway Through 2023
The stock market rebounded in 2023 with top indexes trading higher after 2022, which saw market declines. 
Via Benzinga
Amgen Inc. Dividend Stock Analysis
The company has paid a cash dividend to shareholders every year since 2011 and has increased its dividend payments for 13 consecutive years. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Amgen Out, Rio Tinto In As Morgan Stanley Shuffles Dividend Deck
Via Benzinga
What Will Amgen Buy Next?
The biotech could pursue these two budget-friendly targets. 
Via The Motley Fool
5 High-Yielding Dividend Stocks That Are Bargain Buys
This is a good time for investors to load up on healthcare companies. 
Via The Motley Fool
5 Top Dividend Stocks to Buy in July 2023
All 5 of these dividends stocks appear undervalued. 
Via The Motley Fool
Activision Blizzard Shares up 1.83% Amid Regulators' Blunders
Shares of Microsoft Corp. (NASDAQ: MSFT) declined 1.92% on June 26, more than the broader market, while Activision Blizzard Inc. (NASDAQ: ATVI) rose 1.83%. The S&P 500 declined 0.41% in the session. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Next-Gen Weight-Loss Drugs Set To Up The Game From Ozempic And Mounjaro: WSJ
Via Benzinga
Why Viking Therapeutics Stock Is Crashing Today
Investors seem concerned about the company's competitive positioning in weight loss. 
Via The Motley Fool
Why Amgen Stock Slumped on Monday
Already under fire on the regulatory front, the company is hit with a price-target cut. 
Via The Motley Fool
Russian Insurrection Crushed: 5 Stocks That Continue To Have Exposure To The Country
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
53 54 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.